ADAC adds to management team
Nuclear medicine and RIS/PACS vendor ADAC Laboratories has brought some new faces to its management team. James Haisler has been named COO of the vendor’s Dallas-based healthcare information systems division. Haisler most recently served as
Nuclear medicine and RIS/PACS vendor ADAC Laboratories has brought some new faces to its management team. James Haisler has been named COO of the vendors Dallas-based healthcare information systems division. Haisler most recently served as president of the diagnostic imaging division of Phymatrix, and has also served as president and COO of Dornier Medical Systems. PACS veteran Kevin Flynn has been tapped as vice president of sales at ADAC HCIS. Flynn previously served as vice president of sales for Dome Imaging Systems, and prior to that was national sales manager for the clinical networking division of Siemens Medical Systems.
In other ADAC news, the Milpitas, CA-based firm reported that it has received orders for a record 10 C-PET units in its fiscal first quarter (end-January). In fiscal 1999, ADAC had been booking sales of three to five units per quarter. Among the new customers are Barnes Jewish Hospital in St. Louis, and the San Raffaele Hospital and Research Center in Milan, Italy.
ADAC also announced that it would settle the consolidated class action lawsuit pending against the firm. Under the agreement-in-principle, ADAC would pay the plaintiff class $20 million in full settlement of its claims.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
